Heidi Overton, U.S. President Donald Trump’s nominee to lead the Food and Drug Administration (FDA), pledged to follow the law when making decisions concerning vaccines and the drug mifepristone during a hearing held by the U.S. Senate Committee on Health, Education, Labor, and Pensions to evaluate her nomination.
The hearing comes as the agency seeks to restore stability after a period marked by employee layoffs and the departure of senior officials, in addition to criticism that some of its decisions were influenced by political considerations. If the Senate approves her appointment, Overton would succeed acting Commissioner Kyle Diamantas, who has held the position since former Commissioner Martin Makary resigned in May.
A Political Test for Vaccine Policy
Members of the committee focused their questions on Overton’s position on vaccines, particularly after the White House issued an executive order in August targeting a reduction in the childhood vaccination schedule and the separation of the measles, mumps, and rubella (MMR) vaccine into three separate doses. Overton had described the order as “historic.”
Bill Cassidy, the Republican from Louisiana and chairman of the relevant Senate committee, asked Overton directly whether the MMR vaccine was safe and effective. She answered that it was “safe and effective,” describing it as the best tool currently available for the public response to measles outbreaks. She added that all vaccines marketed in the United States are safe and effective according to the FDA’s assessment, and that she would follow the law when making decisions concerning each product.
The answer carries practical significance because Cassidy referred to previous promises that had not been honored, considering that the independence of the agency’s decisions from political pressure would remain subject to scrutiny if Overton reached the position.
Unsettled Position on Mifepristone
Overton also faced questions from Cassidy and Lisa Murkowski, the Republican from Alaska, about mifepristone, a drug that the FDA authorized to be prescribed by mail and through telehealth consultations. During her work at the America First Policy Institute, Overton had written that the drug was “dangerous.”
During the hearing, she acknowledged that the FDA had concluded that mifepristone met safety and effectiveness standards, but said she did not want to prejudge the outcome of an ongoing safety review. Thus, the hearing produced no immediate regulatory change, but it revealed an issue that will remain under scrutiny if she takes over leadership of the agency.
Accelerating Drug Development and Competing with China
Overton also indicated her support for FDA initiatives aimed at accelerating the early stages of drug research, including the “Operation Trialblazer” initiative. These plans are linked to the increase in drug deals involving discoveries made in China and the potential effects this could have on the United States’ ability to innovate.
She said she would work with the agency’s professional staff to improve various aspects of clinical trials and drug development, with the aim of bringing some of the development back to the United States and accelerating patients’ access to treatments.
What Changes in Practice?
The hearing did not produce a final decision on vaccines or mifepristone, and the date of the vote on Overton’s nomination remains unclear and may be affected by its timing relative to the November midterm elections. However, the hearing provided two main indicators: the continued priority given to institutional stability and reliance on professional staff within the FDA, and the increasing connection between U.S. pharmaceutical policy and competition with China’s biotechnology sector.
According to an assessment by RBC Capital Markets analyst Brian Abrahams, the hearing was positive overall, showing Overton’s focus on U.S. leadership in innovation and her openness to regulatory flexibility and reliance on professional staff. However, the future of her nomination and the extent to which these pledges translate into independent decisions on politically sensitive vaccine and drug issues remain open.